GlassScriptPhysician profile
Sara M Markey
NPI 1477630473
$5,489.74
in general payments reported to CMS, 2019-2025
22 companies · $549 in 2025
The $549 reported for 2025 was more than what a typical Psychiatry provider received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $551 · 2020: $57.56 · 2021: $54.30 · 2022: $2,957 · 2023: $669 · 2024: $652 · 2025: $549.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,870.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,870.15 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neuronetics, INC. | $1,343.52 | 2022 | |
| Brainsway USA INC | $1,233.99 | 2022 | |
| Otsuka America Pharmaceutical, INC. | $510.96 | 2022-2025 | Nuedexta, Rexulti |
| Alkermes, INC. | $421.52 | 2022-2025 | Aristada, Lybalvi, Vivitrol |
| Abbvie INC. | $337.63 | 2021-2025 | |
| Allergan, INC. | $326.11 | 2019-2020 | |
| Neurocrine Biosciences, INC. | $301.18 | 2019-2025 | Ingrezza |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $295.32 | 2022-2025 | Caplyta |
| Axsome Therapeutics, INC. | $283.13 | 2023-2024 | Auvelity |
| Takeda Pharmaceuticals U.S.A., INC. | $145.82 | 2023-2025 | Trintellix |
| Janssen Pharmaceuticals, INC | $120.95 | 2019 | |
| Avanir Pharmaceuticals, INC. | $36.79 | 2020-2022 | |
| Idorsia Pharmaceuticals US INC | $33.03 | 2023 | Quviviq |
| Teva Pharmaceuticals USA, INC. | $28.94 | 2023 | Austedo Xr |
| Tempus Ai, INC | $22.20 | 2024 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $19.24 | 2025 | Cobenfy |
| Eisai INC. | $14.76 | 2021 | |
| Lundbeck LLC | $14.65 | 2019 |
4 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sara Markey listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.